MLTX SECURITIES ALERT: BFA Law Reminds MoonLake Immunotherapeutics Investors with Losses of Important December 15 Securities Class Action Deadline

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, with a deadline for investors to join the case by December 15, 2025 [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [4]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [4]. Allegations and Clinical Data - The lawsuit claims that MoonLake misrepresented its clinical data, asserting that SLK's Nanobody structure provided superior clinical benefits compared to competitors, which was allegedly not true [5][6]. - The company claimed strong clinical data from its Phase 2 MIRA trial, suggesting higher clinical responses and differentiation from competitors [5]. Stock Performance and Impact - Following the disappointing results from the VELA Phase 3 trials reported on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [7].